Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity

Abstract

We investigated whether serum titers of interleukin 10 (IL-10), a cytokine known to shift lymphocyte responses towards humoral immunity, reflect disease activity in systemic lupus erythematosus (SLE). Sera from 72 SLE patients, 25 RA patients and 30 healthy controls were tested for IL-10 by ELISA. Low titers of IL-10 were detected in the serum of 37.5% of SLE patients and in 24% of RA patients but in only 3% of healthy controls. Interestingly, serum IL-10 titers in SLE patients were positively correlated with the SLE Disease Activity Index (SLEDAI) and with anti-DNA antibody titers, but negatively with complement fraction C3 levels. These results indicate that serum IL-10 values reflect SLE disease activity and suggest that overexpression of IL-10 might play a pathogenic role in severe lupus disease.

Keywords

interleukin-10 disease activity

Get full access to this article

View all access options for this article.

References

Mosmann TR , Coffman RL Properties and functions of interleukin-10. Adv Immunol 1994; 56: 1-26.

De Wit D. et al. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol 1993; 150: 361-366.

Heinzel FP et al. Production of interferon γ, interleukin 2, interleukin 4 and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leismaniasis. Proc Natl Acad Sci USA 1991; 88: 7011-7015.

De Waal Malefyt R. et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220.

Rousset F. et al. Interleukin 10 is a potent growth and differentiation factor for activated human B cells. Proc Natl Acad Sci USA 1992; 89: 1890-1893.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.

Bombardier C. et al. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.

Llorente L. et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome and systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1647-1655.

Cush JJ et al. Elevated interleukin 10 levels in patients with rheumatoid arthritis . Arthriti.s Rheum 1995; 38: 96-104.

10.

Ishida H. et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994; 179: 305-310.

11.

Llorente L. et al. Spontaneous production of interleukin 10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993; 4: 421-427.

12.

Llorente L. et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus . J Exp Med 1995; 181: 839-844.

13.

Kanno K. et al. CD5+ B cells as precursors of CD5-IgG anti-DNA antibody-producing B cells in autoimmune-prone NZB/W F1 mice. Ann NY Acad Sci 1992; 651: 576-578.